TLDR
- Yes. As of mid-2026, a licensed prescriber can evaluate you and prescribe ADHD medication, including stimulants, through a live video telehealth visit, without a prior in-person exam [1]
- The federal rule allowing this is temporary. It runs through December 31, 2026, unless it is extended again or replaced by a permanent rule [2]
- Florida law permits telehealth prescribing of Schedule II medications for the treatment of a psychiatric disorder, and ADHD qualifies [4]
- Non-stimulant ADHD medications such as atomoxetine, guanfacine, and clonidine are not Schedule II controlled substances, so these rules do not restrict them [6]
- A real diagnostic evaluation comes first. There is no single test for ADHD, and a careful clinical interview is the foundation of any legitimate diagnosis [8]
- Prescribers may still ask for an in-person visit in some cases, and every prescription must serve a legitimate medical purpose in the usual course of professional practice [1]
Can you get ADHD medication online in Florida?
Yes. As of mid-2026, under current federal and Florida rules, a licensed prescriber can evaluate you and prescribe ADHD medication, including stimulant medication, through a live video telehealth visit, without a prior in-person exam [1]. Conditions apply: the visit must use real-time audio and video, the prescriber must be properly licensed and DEA-registered, and the prescription must serve a legitimate medical purpose [1].
That short answer deserves some context. The rules that make this possible sit at two levels, federal and state, and the federal piece is temporary. If you are an adult with ADHD symptoms, or a parent researching options for your teen, it helps to know exactly what the law allows right now, what it does not, and what a trustworthy telehealth evaluation should look like. The sections below walk through each piece.
What the federal rules say in 2026
Federal law currently allows telehealth prescribing of controlled ADHD medications through December 31, 2026. On December 31, 2025, the DEA and HHS published the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, which took effect January 1, 2026 [1]. Under this rule, a DEA-registered practitioner may prescribe Schedule II through V controlled substances via telemedicine to a patient without having conducted an in-person medical evaluation [1].
A few conditions matter here. The prescription must be issued for a legitimate medical purpose in the usual course of professional practice. For a new patient receiving a Schedule II medication, the visit must happen over an interactive, real-time audio-video connection, not by phone call, email, or questionnaire [1]. The prescriber must hold the proper licenses and DEA registration, and every other DEA regulation still applies [1].
The DEA has said the extension gives the agency time to finalize regulations that balance access to care with safeguards against drug diversion [2]. A proposed permanent framework, called the Special Registrations for Telemedicine rule, was published in January 2025 but had not been finalized as of mid-2026 [1]. Two narrow permanent rules did take effect at the end of 2025, one for buprenorphine treatment and one for Veterans Affairs patients, but neither covers ADHD stimulant prescribing for the general public [1].
The practical takeaway: the current flexibility is real, it is in effect now, and the federal government’s own telehealth resource confirms that a DEA-registered practitioner can prescribe a Schedule II-V controlled substance using telemedicine without a prior in-person evaluation if the required conditions are met [3]. It is scheduled to expire December 31, 2026, unless extended or replaced. Any telehealth practice prescribing stimulants should be upfront about that date rather than implying the arrangement is permanent.
What Florida law says
Florida law separately permits telehealth prescribing of Schedule II medications for psychiatric treatment. Florida Statute 456.47 governs telehealth in the state. Section 456.47(2)(c) states that a telehealth provider may not use telehealth to prescribe a Schedule II controlled substance, then carves out specific exceptions, and the first exception is the treatment of a psychiatric disorder [4]. ADHD is a psychiatric disorder, so stimulant prescribing by telehealth falls within that exception when handled by an appropriately licensed, DEA-registered Florida provider.
Florida’s statute defines telehealth as care delivered through synchronous or asynchronous telecommunications technology, covering assessment, diagnosis, consultation, treatment, and monitoring. It excludes email, fax, and audio-only phone calls [4]. The statute states that a telehealth provider who conducts a patient evaluation sufficient to diagnose and treat the patient is not required to perform a physical exam before providing telehealth services [4].
Put together, federal and Florida law point the same direction in 2026: a live video psychiatric evaluation can lawfully lead to an ADHD prescription, including a stimulant, for a patient located anywhere in Florida.
What telehealth can prescribe, and what may still require an in-person visit
Medications a telehealth prescriber can currently provide
Both stimulant and non-stimulant ADHD medications can currently be prescribed through telehealth in Florida. Stimulants such as amphetamine (found in Adderall) and methylphenidate (found in Ritalin) are Schedule II controlled substances with a recognized potential for misuse and dependence, which is why the rules above exist [5]. They are the most commonly used class of ADHD medicines [7]. Under the federal extension and Florida’s psychiatric exception, a qualified prescriber can start or continue these by video through the end of 2026 [1].
Non-stimulants sit in a different category. The FDA has approved four non-stimulant medications for ADHD symptoms: atomoxetine (Strattera), guanfacine (Intuniv), clonidine (Kapvay), and viloxazine (Qelbree) [6]. These are not Schedule II controlled substances, so the temporary federal telehealth rules do not restrict them. Atomoxetine, for example, is used to increase the ability to pay attention and decrease impulsiveness and hyperactivity in children and adults with ADHD [13]. For some patients, a non-stimulant is the better clinical fit regardless of the regulatory picture.
What telehealth cannot do, and when in-person care still enters the picture
The law sets a floor, not a ceiling, and prescribers keep clinical discretion. A few points worth knowing:
- A prescriber may require an in-person visit case by case. The federal rule authorizes prescribing by telemedicine; it does not force a clinician to prescribe by video if an in-person assessment is clinically warranted [1].
- Controlled medications require monitoring. Expect follow-up visits, dose reviews, and honest conversations about how the medication is working. Ongoing follow-up is part of responsible prescribing for any controlled medication.
- Some testing is in-person by nature. Objective measures like QbTest run on dedicated equipment in an office setting, described more below.
- Audio-only phone calls do not qualify. Both federal and Florida rules require real-time audio and video for this kind of prescribing [1] [4].
- Supply is a separate hurdle. Some manufacturers still reported constraints on certain amphetamine products as of mid-2026, so availability can vary by product, strength, and pharmacy [11]. A prescriber who follows your care over time can help adjust when a pharmacy cannot fill a specific product.
What a legitimate telehealth ADHD evaluation looks like
A legitimate evaluation starts with diagnosis, not with medication. There is no single test to diagnose ADHD [8]. A careful diagnostic process includes a structured clinical interview covering your symptoms, your history, and how those symptoms affect daily functioning. For adults and adolescents over 16, the diagnostic criteria require five or more symptoms of inattention or hyperactivity-impulsivity, evidence that several symptoms were present before age 12, symptoms showing up in two or more settings such as home, school, or work, clear interference with functioning, and a check that another condition does not better explain the picture [8].
That last item matters more than most people expect. Trouble focusing can come from anxiety, depression, sleep problems, or other conditions, and a rushed questionnaire cannot sort that out. A careful evaluation takes time. If a service seems uninterested in your history, never asks about other explanations for your symptoms, or promises medication before any real assessment, that is a reason to look elsewhere. You deserve an evaluation, not a transaction.
The clinical interview portion of an ADHD evaluation works well by video. Rating scales and history-taking translate naturally to a telehealth visit. Objective testing adds another layer. QbTest is an FDA-cleared (510(k)) computerized test that gives clinicians objective measurements of hyperactivity, impulsivity, and inattention to aid in the clinical assessment of ADHD [10]. The test takes about 20 minutes: you respond to a simple attention task on a screen while a motion-tracking camera records movement. It is not a standalone diagnostic tool [10]. It is meant to add objective data to the assessment alongside a clinical interview and rating scales.
ADHD is common, and getting evaluated is a routine part of health care. An estimated 6.0% of U.S. adults, roughly 15.5 million people, had a current ADHD diagnosis based on 2023 data, and about half of adults with ADHD have used telehealth for ADHD services [9]. An estimated 7 million U.S. children ages 3 to 17, about 11.4%, have ever been diagnosed with ADHD [12]. If you are pursuing an evaluation for yourself or your teen, millions of families across the country have faced the same decision.
Getting started with telehealth ADHD care in Florida
Twelve Oaks Psychiatry provides ADHD testing and treatment for adults and adolescents, in person in Cooper City and by HIPAA-compliant telehealth statewide across Florida. Michael Hernandez, APRN, PMHNP-BC, a board-certified psychiatric mental health nurse practitioner, conducts a thorough diagnostic evaluation before any medication decision. The clinical interview can be completed by video from anywhere in Florida. For patients who want objective testing, QbTest is available in person at the Cooper City office at 10400 Griffin Rd, Suite 201, Cooper City, FL 33328.
Michael takes time with each patient. If ADHD medication is appropriate, ongoing medication management includes scheduled follow-ups to review how treatment is going and adjust when needed, which is exactly the kind of monitoring that responsible controlled-substance prescribing requires. Same-day appointments are available, and the practice accepts Blue Cross Blue Shield, Aetna, Cigna, UnitedHealthcare, and Medicare. Patients are encouraged to confirm in-network status with their plan.
To ask a question or schedule a visit, call (954) 947-1130 or contact us online. Whether you live near Cooper City or hundreds of miles away in Florida, an evaluation is closer than it may seem.
Frequently Asked Questions
Can I get ADHD medication online in Florida without seeing someone in person first?
Yes, as of mid-2026. Federal rules allow a DEA-registered prescriber to prescribe Schedule II-V controlled substances by telemedicine without a prior in-person evaluation, through December 31, 2026 [1]. Florida law permits telehealth Schedule II prescribing for the treatment of a psychiatric disorder [4]. The visit must use live audio and video [1], and a prescriber may still ask for an in-person visit case by case.
Can stimulants like Adderall be prescribed by telehealth in Florida?
Yes, currently. Amphetamine and methylphenidate products are Schedule II controlled substances [5], and both the federal temporary extension and Florida’s psychiatric-disorder exception permit prescribing them by real-time video telehealth [1] [4]. Note that some manufacturers still reported supply constraints on certain amphetamine products as of mid-2026, so pharmacy availability varies [11].
Which ADHD medications are not controlled substances?
The FDA has approved four non-stimulants for ADHD symptoms: atomoxetine (Strattera), guanfacine (Intuniv), clonidine (Kapvay), and viloxazine (Qelbree) [6]. These are not Schedule II controlled substances, so the temporary federal telehealth rules do not restrict them, and they can be prescribed through telehealth without the same regulatory time limits.
What happens to telehealth prescribing after December 31, 2026?
That is not yet settled. The current federal flexibility expires December 31, 2026, unless the DEA extends it again or finalizes a permanent rule [1]. The DEA has stated it is working on regulations that balance access to care with safeguards against diversion [2]. A practice that follows your care over time can help you plan for any changes.
Can my teenager be evaluated for ADHD through telehealth?
The clinical interview portion of an adolescent evaluation can be done by video. Diagnosis for adolescents 17 and older requires five or more symptoms, with several present before age 12, appearing in two or more settings, and clearly interfering with functioning [8]. At Twelve Oaks Psychiatry, adolescents can complete QbTest in person at the Cooper City office as part of a full evaluation, with parents involved throughout.
Do I have to keep doing appointments after I get a prescription?
Yes. Controlled ADHD medications call for ongoing monitoring and follow-up visits so your prescriber can review symptoms, side effects, and dosing. This is a feature, not a hurdle: regular medication management visits are how treatment gets tuned to you, and they are a standard part of safe, attentive psychiatric care.
What if my symptoms feel urgent or I am in crisis?
If you are in immediate danger or feel you might harm yourself or someone else, call 911 right away. For crisis support, call or text 988, the Suicide and Crisis Lifeline. In many Florida communities, you can call 211 for crisis information and referrals to local resources.
HIPAA and Medical Disclaimer
This blog is general education, not medical advice, diagnosis, or treatment. Reading this does not create a clinician-patient relationship.
If you feel you might harm yourself or someone else, or you are in immediate danger, call 9-1-1 right away.
For crisis support, you can call or text 988. Florida lists 2-1-1 as a resource for crisis information and referrals in many communities.
Privacy note: Do not share sensitive personal health information through public comments, unsecured email, or social media. For care questions, use a secure patient portal or call an office line so your information can be handled privately, consistent with HIPAA expectations for health information privacy.
Citations
[1] Federal Register, Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (December 31, 2025)
[2] U.S. Drug Enforcement Administration, DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care (December 31, 2025)
[3] Telehealth.HHS.gov, Prescribing Controlled Substances via Telehealth
[4] Florida Statute 456.47, Use of Telehealth to Provide Services (Florida Senate)
[5] DEA Diversion Control Division, Controlled Substance Schedules
[6] U.S. Food and Drug Administration, Treating and Dealing with ADHD
[7] MedlinePlus, Attention Deficit Hyperactivity Disorder
[8] Centers for Disease Control and Prevention, Diagnosing ADHD
[9] CDC MMWR, ADHD Diagnosis, Treatment, and Telehealth Use in Adults (October to November 2023 data)
[10] FDA 510(k) Summary, QbTest (K122149)
[11] openFDA Drug Shortages Database, Amphetamine Products
[12] Centers for Disease Control and Prevention, Data on ADHD
[13] MedlinePlus, Atomoxetine